{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-tumor+B&page=7", "query": { "intervention": "Anti-tumor B", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 664, "total_pages": 67, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-tumor+B&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-tumor+B&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T03:03:34.282Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06900595", "title": "Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Adrenal Cortical Carcinoma", "Metastatic Adrenal Cortical Carcinoma", "Recurrent Adrenal Cortical Carcinoma", "Stage III Adrenal Cortical Carcinoma AJCC v8", "Stage IV Adrenal Cortical Carcinoma AJCC v8", "Unresectable Adrenal Cortical Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 48, "start_date": "2026-02-22", "completion_date": "2029-06-02", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-12T03:03:34.282Z", "location_count": 81, "location_summary": "Phoenix, Arizona • La Jolla, California • Madera, California + 60 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Madera", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06900595" }, { "nct_id": "NCT05287945", "title": "Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Orellanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncorena AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2023-08-04", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-12T03:03:34.282Z", "location_count": 6, "location_summary": "Orange, California • Palo Alto, California • San Francisco, California + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05287945" }, { "nct_id": "NCT04200963", "title": "A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Urothelial Carcinoma Bladder", "Bladder Cancer", "Bladder Disease", "Solid Tumor", "Solid Carcinoma", "Solid Tumor, Adult", "Metastatic Cancer", "Advanced Solid Tumor", "Advanced Cancer", "Metastatic Bladder Cancer", "Metastatic Urothelial Carcinoma", "Locally Advanced Solid Tumor", "Neoplasms", "Neoplasm Metastasis", "Neoplasm Malignant", "Neoplasm, Bladder", "Urothelial Neoplasm", "Neoplasm, Urinary Bladder", "Bladder Neoplasm", "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "IK-175", "type": "DRUG" }, { "name": "IK-175 and nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ikena Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-12-18", "completion_date": "2023-07-18", "has_results": false, "last_update_posted_date": "2024-03-15", "last_synced_at": "2026-10-12T03:03:34.282Z", "location_count": 10, "location_summary": "Gilbert, Arizona • Sarasota, Florida • Chicago, Illinois + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04200963" }, { "nct_id": "NCT03448393", "title": "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Leukemia, Lymphocytic, B Cell", "B-Cell Lymphoma", "B-Cell Leukemia", "Acute Lymphoid Leukemia", "B-Non Hodgkin Lymphoma", "B-NHL", "B-All", "Acute Lymphoblastic Leukemia", "Acute Lymphocytic Leukemia" ], "interventions": [ { "name": "CD19/CD22 CAR T-Cells", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" }, { "name": "Anti-emetic", "type": "OTHER" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Brain", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone marrow biopsy", "type": "PROCEDURE" }, { "name": "Cardiac MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 54, "start_date": "2018-03-26", "completion_date": "2025-01-13", "has_results": true, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-12T03:03:34.282Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03448393" }, { "nct_id": "NCT04052204", "title": "Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Metastatic Castration Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "avelumab", "type": "DRUG" }, { "name": "Bempegaldesleukin", "type": "DRUG" }, { "name": "talazoparib", "type": "DRUG" }, { "name": "enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-12-30", "completion_date": "2020-09-29", "has_results": true, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-10-12T03:03:34.282Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04052204" }, { "nct_id": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Bladder Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Merkel Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage III Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Merkel Cell Carcinoma AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Plinabulin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-04-14", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-12T03:03:34.282Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04902040" }, { "nct_id": "NCT00296023", "title": "Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 25, "start_date": "1999-01", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2012-10-04", "last_synced_at": "2026-10-12T03:03:34.282Z", "location_count": 2, "location_summary": "Berkeley, California • San Francisco, California", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00296023" }, { "nct_id": "NCT07811297", "title": "A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Endometrial Neoplasms", "Ovarian Neoplasms", "Soft Tissue Sarcoma (STS)", "Glioblastoma" ], "interventions": [ { "name": "AL58805", "type": "DRUG" }, { "name": "AL3818", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" }, { "name": "CCNU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advenchen Pharmaceuticals, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2026-09-01", "completion_date": "2031-09-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-12T03:03:34.282Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07811297" }, { "nct_id": "NCT03217747", "title": "Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Castration-Resistant Prostate Carcinoma", "Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Metastatic Prostate Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "Refractory Malignant Solid Neoplasm", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Ivuxolimab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Utomilumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2017-08-02", "completion_date": "2026-04-30", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-12T03:03:34.282Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03217747" }, { "nct_id": "NCT01159964", "title": "Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer, Non-Small Cell" ], "interventions": [ { "name": "Immunotherapeutic GSK2302032A, different formulations", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2010-07-20", "completion_date": "2014-09-10", "has_results": false, "last_update_posted_date": "2018-06-18", "last_synced_at": "2026-10-12T03:03:34.282Z", "location_count": 7, "location_summary": "Newark, Delaware • Boston, Massachusetts • Rochester, Minnesota + 4 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01159964" } ] }